Adjuvant chemotherapy in a unique population of patients with gastric cancer undergoing surgery
Uslu, A.; Karaca, C.; Nart, A.; Adagülü, H.; Aykas, A.; Gürkan, A.; Dogan, M.
Hepato-Gastroenterology 51(58): 1245-1248
2004
ISSN/ISBN: 0172-6390 PMID: 15239288 Document Number: 580250
Background/Aims: Total gastrectomy with D2 dissection theoretically removes the gross primary tumor with its potential route of dissemination, that is locoregional lymph nodes. Complementary therapy for the control of systemic microscopic disease should be taken into consideration in patients whom surgery with curative intent was performed. Methodology: Twenty-eight patients with moderately differentiated, locally advanced gastric carcinoma underwent total gastrectomy with D2 lymph node dissection. The operative mortality rate was 0% in this series. Fifteen patients received six courses of adjuvant 5-FU + leucovorin in doses of 425Mg/m2/d and 20mg/m2/d respectively in five-day cycles month ly. The remaining 13 patients constituted the control (surgery only) group. Results: The mean disease-free and overall survival rates were 41 and 48 months (p: 0.78) and 42 and 53 months (p: 0.43) in the control and chemotherapy groups, respectively. The odds ratio for crude mortality was 0.7. Conclusions: Although statistical significance has not been achieved in this study, a trend toward adjuvant chemotherapy has emerged in that unique group of patients with moderately differentiated (intestinal type) adenocarcinoma. of the stomach undergoing curative surgery.